FASLG and neoplasm: More importantly, this combination therapy also increases downstream 7-day activated (Fas-L+) CTL recruitment and TIL ratios of up to 5-fold within the periablational rim, underscoring the ability of upstream and early immune stimulation to activate later stages in anti-tumor immunity in this clinical setting.